252954-54-4

Basic information

• Product Name: Ethanone, 1-(2,4-dichlorophenyl)-2-(2,4-dimethyl-1H-imidazol-1-yl)-
• Synonyms: Ethanone, 1-(2,4-dichlorophenyl)-2-(2,4-dimethyl-1H-imidazol-1-yl)-
• CAS NO: 252954-54-4
• Molecular Formula: C13H12Cl2N2O
• Molecular Weight: 283.15
• Mol File: 252954-54-4.mol

Chemical Properties

• Appearance: /
• CAS DataBase Reference: Ethanone, 1-(2,4-dichlorophenyl)-2-(2,4-dimethyl-1H-imidazol-1-yl)-(CAS DataBase Reference)
• NIST Chemistry Reference: Ethanone, 1-(2,4-dichlorophenyl)-2-(2,4-dimethyl-1H-imidazol-1-yl)-(252954-54-4)
• EPA Substance Registry System: Ethanone, 1-(2,4-dichlorophenyl)-2-(2,4-dimethyl-1H-imidazol-1-yl)-(252954-54-4)

Safety Data

• Hazardous Substances Data: 252954-54-4(Hazardous Substances Data)

Upstream product

• 930-62-1 2,4-Dimethylimidazole 
• 2631-72-3 2,4-dichlorophenacyl bromide 
• 541-73-1 1,3-Dichlorobenzene 

Relevant articles and documents

Novel Tetrazole-Containing Analogues of Itraconazole as Potent Antiangiogenic Agents with Reduced Cytochrome P450 3A4 Inhibition

Itraconazole has been found to possess potent antiangiogenic activity, exhibiting promising antitumor activity in several human clinical studies. The wider use of itraconazole in the treatment of cancer, however, has been limited by its potent inhibition of the drug metabolizing enzyme cytochrome P450 3A4 (CYP3A4). In an effort to eliminate the CYP3A4 inhibition while retaining its antiangiogenic activity, we designed and synthesized a series of derivatives in which the 1,2,4-triazole ring is replaced with various azoles and nonazoles. Among these analogues, 15n with tetrazole in place of 1,2,4-triazole exhibited optimal inhibition of human umbilical vein endothelial cell proliferation with an IC50 of 73 nM without a significant effect on CYP3A4 (EC50 > 20 μM). Similar to itraconazole, 15n induced Niemann-Pick C phenotype (NPC phenotype) and blocked AMPK/mechanistic target of rapamycin signaling. These results suggest that 15n is a promising angiogenesis inhibitor that can be used in combination with most other known anticancer drugs.

Inhibitors of glycogen synthase kinase 3

New pyrimidine or pyridine based compounds, compositions and methods of inhibiting the activity of glycogen synthase kinase (GSK3) in vitro and of treatment of GSK3 mediated disorders in vivo are provided. The methods, compounds and compositions of the invention may be employed alone, or in combination with other pharmacologically active agents in the treatment of disorders mediated by GSK3 activity, such as diabetes, Alzheimer's disease and other neurodegenerative disorders, obesity, atherosclerotic cardiovascular disease, essential hypertension, polycystic ovary syndrome, syndrome X, ischemia, traumatic brain injury, bipolar disorder, immunodeficiency or cancer.